DrugPatentWatch Database Preview
PAROXETINE HYDROCHLORIDE Drug Profile
or, see our see our flat-rate plans
Which patents cover Paroxetine Hydrochloride, and when can generic versions of Paroxetine Hydrochloride launch?
The generic ingredient in PAROXETINE HYDROCHLORIDE is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Fifty-five suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the paroxetine hydrochloride profile page.
Summary for PAROXETINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 17 |
| Suppliers / Packagers: | 52 |
| Bulk Api Vendors: | 69 |
| Clinical Trials: | 222 |
| Patent Applications: | 748 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PAROXETINE HYDROCHLORIDE |
| DailyMed Link: | PAROXETINE HYDROCHLORIDE at DailyMed |
Pharmacology for PAROXETINE HYDROCHLORIDE
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
Synonyms for PAROXETINE HYDROCHLORIDE
| (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)-methyl)piperidine hydrochloride |
| (-)-trans-4-(-4-fluorophenyl)-3-(3,4-methylenedioxy-phenoxymethyl)-piperidine hydrochloride |
| (-)-trans-4-(-4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)-piperidine hydrochloride |
| (-)-trans-4-(4-fluorophenyl)-3-(3,4-methylene dioxyphenoxymethyl)-piperidine hydrochloride |
| (-)-trans-paroxetine hydrochloride |
| (-)TRANS-3-[(1,3-BENZODIOXOL-5-YLOXY) METHYL]-4-(4-FLUOROPHENYL) PAROXETINE HYDROCHLORIDE |
| (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidine hydrochloride |
| (3S-TRANS)-3-[(1,3-BENZODIOXOL-5-YLOXY)METHYL]-4-(4-FLUOROPHENYL)PIPERIDINE HYDROCHLORIDE |
| (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride; Paroxetine Hydrochloride Anhydrous; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; 3-[(1,3-benzodioxol-5-yl |
| (3S,4R)-(-)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine Hydrochloride |
| (3S,4R)-3-((BENZO[D][1,3]DIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE HCL |
| (3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine hydrochloride |
| (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine hydrochloride |
| (3S,4R)-3-[(1,3-BENZODIOXOL-5-YLOXY)METHYL]-4-(4-FLUOROPHENYL)-PIPERIDINE HYDROCHLORIDE |
| (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride |
| (S)-3-(BENZO[1,3]DIOXOL-5-YLOXYMETHYL)-4-(4-FLUORO-PHENYL)-PIPERIDINE HYDROCHLORIDE |
| 110429-35-1 |
| 110429-35-1(hemihydrate) 61869-08-7 |
| 3I3T11UD2S |
| 61869-08-7 (Parent) |
| 78246-49-8 |
| AB0008509 |
| AB1004558 |
| AC1L1XYV |
| AK-49032 |
| AKOS015849162 |
| AKOS015907108 |
| AN-15600 |
| ANW-49202 |
| API0003757 |
| Aropax 20 |
| AX8022605 |
| BG0380 |
| BR-49032 |
| BRL 29060 hydrochloride |
| BRL 29060A |
| BRL29060A |
| C19H20FNO3.HCl |
| C19H21ClFNO3 |
| CCG-39866 |
| CHEBI:7944 |
| CHEMBL1708 |
| CS-2611 |
| D05374 |
| DTXSID50228914 |
| EU-0100095 |
| GELRVIPPMNMYGS-RVXRQPKJSA-N |
| H29P351 |
| HMS1922B11 |
| HSDB 7175 |
| HY-B0492 |
| J10285 |
| KS-00000JOT |
| KS-5097 |
| LP00095 |
| LS-114251 |
| MFCD03658863 |
| MLS002222322 |
| MolPort-003-666-523 |
| NCGC00093597-01 |
| NCGC00260780-01 |
| NSC-758654 |
| NSC758654 |
| P1977 |
| Paroxat |
| paroxatene |
| PAROXETIN HYDROCHLORIDE |
| paroxetine (hydrochloride) |
| paroxetine (Paxil) |
| Paroxetine Hcl |
| Paroxetine hydrochloride (USP) |
| Paroxetine hydrochloride [USAN] |
| Paroxetine hydrochloride [USP] |
| Paroxetine hydrochloride hemihydrate |
| Paroxetine hydrochloride hemihydrate (MW = 374.83) |
| Paroxetine or other medication - algorithm used |
| paroxetinehydrochloride |
| Pharmakon1600-01504085 |
| Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, hydrochloride, (3S-trans)- |
| Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, hydrochloride, (3S,4R)- |
| Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, hydrochloride,(3S-trans)- |
| S-2491 |
| S3005 |
| SCHEMBL33348 |
| SDB 7175 |
| SMR001307264 |
| SPECTRUM1504085 |
| ST24025708 |
| ST51054156 |
| TC-137947 |
| TL8005348 |
| Tox21_500095 |
| UNII-3I3T11UD2S |
| YF10047 |
| Z1741971218 |
US Patents and Regulatory Information for PAROXETINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 078194-003 | Jun 29, 2007 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Oxford Pharms | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 076968-002 | Jun 21, 2010 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Teva Pharms | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 077082-003 | Jun 29, 2007 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Teva | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET;ORAL | 076618-003 | Aug 15, 2005 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
